We are live on ! Find out more
SPRB

Spruce Biosciences
SPRB

38 hedge funds and large institutions have $68.7M invested in Spruce Biosciences in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

10% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 10

8% less capital invested

Capital invested by funds: $74.5M → $68.7M (-$5.8M)

14% less funds holding

Funds holding: 44 → 38 (-6)

60% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 10

Holders
38
Holders Change
-6
Holders Change %
-13.64%
% of All Funds
0.6%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
4
Increased
11
Reduced
10
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AI
Acuitas Investments
Washington
+$613K
2
Two Sigma Advisers
Two Sigma Advisers
New York
+$451K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$351K
4
Verition Fund Management
Verition Fund Management
Connecticut
+$272K
5
BlackRock
BlackRock
New York
+$244K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$3.63M
2
CH
CVI Holdings
Delaware
-$1.04M
3
AC
Armistice Capital
New York
-$958K
4
Goldman Sachs
Goldman Sachs
New York
-$404K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$204K
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$14.5M – – –
AC
2
Armistice Capital
New York
$7.52M -$958K -5,733 -11%
RVM
3
RiverVest Venture Management
Missouri
$6.31M – – –
CG
4
Carlyle Group
District of Columbia
$6.23M – – –
RSCM
5
Rock Springs Capital Management
Maryland
$5.87M – – –
5VM
6
5AM Venture Management
California
$5.08M – – –
OFM
7
Omega Fund Management
Massachusetts
$4.65M – – –
ACM
8
Aisling Capital Management
New York
$2.59M – – –
ACM
9
AIGH Capital Management
Maryland
$2.39M +$15.5K +93 +0.6%
Verition Fund Management
10
Verition Fund Management
Connecticut
$2.33M +$272K +1,625 +13%
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$2.15M – – –
SCV
12
Sands Capital Ventures
Virginia
$1.69M – – –
Millennium Management
13
Millennium Management
New York
$1.24M -$69.6K -416 -5%
DCM
14
DAFNA Capital Management
California
$671K – – –
WVP
15
Worth Venture Partners
New Jersey
$597K +$15.7K +94 +3%
AI
16
Acuitas Investments
Washington
$591K +$613K +3,667 New
Vanguard Group
17
Vanguard Group
Pennsylvania
$563K +$34.3K +205 +6%
BlackRock
18
BlackRock
New York
$561K +$244K +1,462 +72%
Two Sigma Advisers
19
Two Sigma Advisers
New York
$516K +$451K +2,699 +539%
Renaissance Technologies
20
Renaissance Technologies
New York
$514K +$176K +1,053 +49%
Two Sigma Investments
21
Two Sigma Investments
New York
$490K +$145K +866 +40%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$469K +$351K +2,097 +260%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$197K -$1.5K -9 -0.7%
BCM
24
Bridgeway Capital Management
Texas
$183K – – –
Citadel Advisors
25
Citadel Advisors
Florida
$153K -$3.63M -21,698 -96%
1
2

SPRB Hedge Fund Activity: Q2 2023 in Review

38 of the 6,372 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q2 2023, worth a combined $68.7M — down 7.8% from $74.5M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of SPRB and 4 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 11 added.

The largest buyer was Acuitas Investments, opening a new position worth an estimated $613K. The largest seller was Citadel Advisors, cutting an estimated $3.63M.

  • 38 institutional investors held Spruce Biosciences (SPRB) as of Q2 2023, down from 44 in Q1 2023.
  • Funds reported $68.7M of Spruce Biosciences stock for Q2 2023, down 7.8% quarter-over-quarter.
  • 4 funds opened new Spruce Biosciences positions in Q2 2023 and 10 closed out, a net change of -6 holders.
  • The largest Spruce Biosciences buyer in Q2 2023 was Acuitas Investments, an estimated $613K added.
  • The largest Spruce Biosciences seller in Q2 2023 was Citadel Advisors, an estimated $3.63M sold.

Based on aggregated 13F filings for Q2 2023.